Consensus Recursion Pharmaceuticals, Inc.

Equities

RXRX

US75629V1044

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 18/09/2024 BST			5-day change	1st Jan Change
6.910 ^USD	+2.22%		+7.13%	-29.92%

09-03	Jefferies Cuts Price Target on Recursion Pharmaceuticals to $6 From $8, Maintains Hold Rating	MT
09-03	Recursion Pharmaceuticals Says REC-994 Phase 2 Trial Shows Safety and Efficacy Trends	MT

Evolution of the Average Target: Recursion Pharmaceuticals, Inc.

Evolution of the Target Price: Recursion Pharmaceuticals, Inc.

Changes in Analyst Recommendations: Recursion Pharmaceuticals, Inc.

b6a673f4b4f978a5a9e029c05c7c6a4a._zrKUEKS5I36NrIl_Cq5KIEA50DuLBpCmfCNvpW7iM0.jAirBXfeleOccdtAiVD7Q8lovjebSVN6yJnCyabL2524CJ86cuKu55Jc8w~1dcd84e9bddff548e7ac20f47d6e4795

Analysts' recommendations: Recursion Pharmaceuticals, Inc.

Jefferies Cuts Price Target on Recursion Pharmaceuticals to $6 From $8, Maintains Hold Rating	09-03	MT
KeyBanc Cuts Price Target on Recursion Pharmaceuticals to $12 From $16, Maintains Overweight Rating	07-11	MT
Jefferies Initiates Recursion Pharmaceuticals at Hold With $8 Price Target	07-09	MT
Recursion Pharmaceuticals Insider Sold Shares Worth $278,880, According to a Recent SEC Filing	06-17	MT
Recursion Pharmaceuticals Insider Sold Shares Worth $871,000, According to a Recent SEC Filing	06-07	MT
Recursion Pharmaceuticals Insider Sold Shares Worth $367,007, According to a Recent SEC Filing	04-18	MT
Needham Raises Price Target on Recursion Pharmaceuticals to $17 From $15, Maintains Buy Rating	02-28	MT
TD Cowen Starts Recursion Pharmaceuticals With Market Perform Rating	01-26	MT
JPMorgan Trims Price Target on Recursion Pharmaceuticals to $10 From $11, Maintains Neutral Rating	11-13	MT
Needham Adjusts Recursion Pharmaceuticals Price Target to $15 From $17, Maintains Buy Rating	11-10	MT
KeyBanc Adjusts Price Target on Recursion Pharmaceuticals to $15 From $12, Maintains Overweight Rating	13/07/23	MT
Berenberg Bank Adjusts Recursion Pharmaceuticals Price Target to $35 From $33, Maintains Buy Rating	13/07/23	MT
Morgan Stanley Lifts Price Target on Recursion Pharmaceuticals to $11 From $8 Amid NVIDIA Partnership, Keeps Equalweight Rating	13/07/23	MT
Keybanc Adjusts Price Target on Recursion Pharmaceuticals to $12 From $20, Keeps Overweight Rating	09/05/23	MT
Needham Starts Recursion Pharmaceuticals at Buy With $17 Price Target	16/03/23	MT
Berenberg Bank Adjusts Recursion Pharmaceuticals Price Target to $33 From $42, Maintains Buy Rating	02/02/23	MT
SVB Securities Adjusts Price Target on Recursion Pharmaceuticals to $8 From $9, Maintains Market Perform Rating	23/01/23	MT
Berenberg Bank Adjusts Recursion Pharmaceuticals Price Target to $42 From $38, Maintains Buy Rating	16/11/22	MT
Goldman Sachs Adjusts Price Target on Recursion Pharmaceuticals to $9 From $8, Maintains Neutral Rating	09/11/22	MT
KeyBanc Starts Recursion Pharmaceuticals at Overweight With $20 Price Target	16/09/22	MT
Goldman Sachs Adjusts Recursion Pharmaceuticals' Price Target to $8 From $7, Keeps Neutral Rating	11/08/22	MT
Berenberg Bank Adjusts Recursion Pharmaceuticals' Price Target to $38 From $36, Maintains Buy Rating	22/06/22	MT
Goldman Sachs Lowers Recursion Pharmaceuticals' Price Target to $7 From $9, Neutral Rating Kept	24/05/22	MT
BofA Securities Downgrades Recursion Pharmaceuticals to Neutral from Buy	18/04/22	MT
Goldman Sachs Adjusts Recursion Pharmaceuticals' Price Target to $10 from $32, Keeps Neutral Rating	24/03/22	MT

More recommendations

Sector Comparison:

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analyst Opinion	4m Revision of opinion	Divergence of analysts' opinions	Divergence of Target Price	Ecart obj. / dr
	RECURSION PHARMACEUTICALS, INC.					+50.04%
	VERTEX PHARMACEUTICALS INCORPORATED					+5.93%
	REGENERON PHARMACEUTICALS, INC.					+1.35%
	ARGENX SE					+5.99%
	BIONTECH SE					-6.66%
	BEIGENE, LTD.					+38.20%
	SUMMIT THERAPEUTICS INC.					+13.21%
	GENMAB A/S					+35.77%
	WUXI APPTEC CO., LTD.					+46.89%
	VAXCYTE, INC.					+24.20%
	Average					+21.49%
	Weighted average by Cap.					+9.40%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

6.760USD

Average target price

10.14USD

Spread / Average Target

+50.04%

High Price Target

14.00USD

Spread / Highest target

+107.10%

Low Price Target

6.000USD

Spread / Lowest Target

-11.24%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Needham & Co.
TD Cowen
JPMorgan Chase
KeyBanc Capital Markets
Morgan Stanley
Berenberg Bank
SVB Securities LLC
Goldman Sachs
BofA Securities
SVB Leerink
J.P. Morgan Chase